Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | PTGFR | P43088 | 1/20 | 0.33 |
| ▸ | PTGIR | P43119 | 1/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
| ▸ | OXTR | P30559 | 2/20 | 0.32 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2969352 | 0.94 | ALDH1A1 (0.35) | EDNRARORC | |
| SCHEMBL2976766 | 0.92 | TBXA2R (0.35) | EDNRAPTGER1PTGER3TBXA2RPTGER4 | |
| SCHEMBL3066934 | 0.90 | ALOX5AP (0.33) | EDNRARORC | |
| SCHEMBL3060060 | 0.89 | OPRM1 (0.37) | PTGER1PTGER3TBXA2RPTGER4PTGFR | |
| SCHEMBL2969407 | 0.88 | ALDH1A1 (0.35) | PTGER1PTGER3TBXA2RPTGER4PTGFR | |
| SCHEMBL2970929 | 0.86 | F10 (0.34) | EDNRAPTGER1PTGER3RORCTBXA2R | |
| SCHEMBL2978222 | 0.86 | PSMB5 (0.33) | EDNRAPTGER1PTGER3TBXA2RPTGER4 | |
| SCHEMBL3050703 | 0.84 | TRPV1 (0.37) | PTGER1PTGER3RORC | |
| SCHEMBL3050707 | 0.83 | CD274 (0.35) | RORC | |
| SCHEMBL2977806 | 0.82 | FEN1 (0.33) | PTGER1PTGER3TBXA2RPTGER4PTGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011597-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8735625-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140046075-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8394846-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120129900-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20100267788-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267788-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | EDNRA 5/4885PTGER1 107/4885PTGER3 121/4885 |
| US-20150011597-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | EDNRA 5/4885PTGER1 107/4885PTGER3 121/4885 |
| US-20140046075-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | EDNRA 5/4885PTGER1 107/4885PTGER3 121/4885 |
| US-20120129900-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | EDNRA 5/4885PTGER1 107/4885PTGER3 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.